Filing summary
Company and period: The supplied filing is Targacept, Inc.’s unaudited Form 10-Q for the quarter ended March 31, 2013—not a filing identified as Gyre Therapeutics, Inc. Investors should verify the issuer and filing before relying on this summary.
Business context
Targacept was a clinical-stage biopharmaceutical company developing neuronal nicotinic receptor therapeutics for nervous-system disorders. It reported no product sales and relied primarily on collaboration payments, financing and grants. Following workforce reductions and laboratory closures in 2012, it focused on clinical programs. Key programs included TC-5619 for schizophrenia, TC-5214 for overactive bladder, TC-1734 for Alzheimer’s disease and AstraZeneca’s AZD1446 collaboration.
Financial results
| Metric | Q1 2013 | Q1 2012 |
|---|---|---|
| Operating revenue | $3.5 million | $22.9 million |
| Research and development expense | $8.3 million | $17.8 million |
| General and administrative expense | $3.5 million | $3.1 million |
| Operating loss / income | $(8.3) million | $2.0 million |
| Net loss / income | $(8.1) million | $2.3 million |
| Basic and diluted EPS | $(0.24) | $0.07 |
| Operating cash flow | $(9.3) million | $(24.9) million |
Revenue fell $19.3 million year over year, principally because the prior-year quarter included $21.8 million of recognition from the $200 million TC-5214 major-depression collaboration upfront payment. That payment had been fully recognized by June 2012. Q1 2013 collaboration revenue included $3.5 million recognized after AstraZeneca removed TC-1734 from its collaboration, including $3.1 million of previously deferred amounts. No grant revenue was reported in Q1 2013. Gross margin is not applicable to the reported results; the filing provides no product-sales margin.
At March 31, cash and cash equivalents were $69.9 million and marketable securities totaled $105.2 million, for combined liquidity of approximately $175.1 million, versus $184.9 million at December 31, 2012. Total assets were $178.7 million; total liabilities were $9.3 million. Debt was approximately $1.8 million, including $0.9 million current, with no remaining borrowing capacity under the equipment loan facility. The accumulated deficit was $242.0 million.
Material changes and unusual items
- R&D expense decreased $9.5 million, reflecting 2012 workforce reductions, laboratory closures and completion of the TC-5214 Phase 3 MDD program; clinical-trial spending continued.
- G&A expense increased $0.4 million. Q1 included $0.5 million of incremental noncash stock compensation from a departing executive’s option modifications and approximately $0.3 million of severance and related charges.
- In March 2013, AstraZeneca amended its ongoing alliance to permit development and commercialization of licensed compounds in any therapeutic area and exercised its right to terminate TC-1734 from the collaboration. Targacept recognized remaining deferred revenue; future AZD1446 milestone payments remain contingent and uncertain.
- Net cash declined $12.4 million during the quarter. Operating cash use improved year over year, while investing cash flow reflected net purchases of marketable securities.
Outlook, commentary and risks
Management expected existing capital resources to fund operations through at least the end of 2015, excluding potential AZD1446 milestones, while warning that plans could change and additional funds might be needed sooner. It expected 2013 revenue to be substantially below 2012, with no previously received collaboration payments left to recognize after April 1, 2013. It expected full-year 2013 R&D expense to decline from 2012 but remain significant, including for TC-5619, TC-1734 and the planned TC-5214 overactive-bladder Phase 2b trial.
Key risks include clinical-trial outcomes and timing, regulatory acceptance of trial designs, dependence on collaborators and uncertain milestone receipts, the ability to obtain additional financing or partnerships, and potential dilution or program reductions if funding is insufficient. Management reported disclosure controls were effective and no material change in internal control over financial reporting during the quarter. The filing states that a 2010 federal tax return was under examination; tax attributes may be limited, including by ownership-change rules.
Important facts for investors to verify
- Confirm the issuer: the source document names Targacept, Inc., whereas the request metadata names Gyre Therapeutics, Inc.
- Verify the status and results of the ongoing TC-5619 and TC-1734 trials and the planned TC-5214 overactive-bladder study; the filing does not provide subsequent outcomes.
- Assess the assumptions behind management’s runway estimate through end-2015, including clinical spending, collaboration receipts and financing availability.
- Confirm the scope and effect of the AstraZeneca amendment and TC-1734 termination, and whether any AZD1446 milestones were achieved.
- Review the executive separation and option-modification costs, outstanding debt schedule and any developments in the tax examination.